Pfizer shares tumble after setback with breast cancer treatment

Shares of Pfizer fell nearly 7 percent on Monday after an independent data monitoring committee determined the drugmaker’s breast cancer treatment was unlikely to meet the main goal of a late-stage study. The treatment, Ibrance, was being tested along with the standard of care for early breast cancer in men and women, against standard of… Continue reading at New York Post